Venture Partner focused on life sciences. In November 2013, AjuIB Investment established a venture capital fund to focus on investments in novel technology platforms and therapeutics in the life sciences. The fund focus is on identifying and supporting capital efficient businesses with broad technology applicability and strong management teams. AjuIB Investment is also focused on creating business and technology relationships between US and Korean life sciences companies.

Board member of Molecular Templates, a biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapeutics with distinct advantages over existing antibody drug conjugates (ADCs). This biologic platform technology is being used to develop multiple therapies across a wide range of cancers. The Company’s lead compound, MT-3724, an immunotoxin targeting CD20, and is in Phase I of clinical testing.

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1 is specifically focused on the biology of cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells. In partcular, G1's expertise is in targeting CDK4 and CDK6, collectively known as CDK4/6. The Company is developing two highly potent and selective CDK4/6 inhibitors for the treatment of a variety of cancers.

Advisory and lending services to life sciences companies

Executive Vice President with responsibilities including strategic finance, business development, IR/PR etc.

Investor in Life Sciences companies

Life Sciences Investment Banking

Vice President of Investment Banking

Healthcare financial and strategic consulting